RxDoctor Payments Data

Chase Jacomini

Psychiatric/Mental Health · Framingham, MANPI 1053960385

Payments from drug & device makers

$1,158in general payments, 2019–2025

Across 47 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$197
  • Lundbeck LLC$172
  • Neurocrine Biosciences, Inc.$163
  • Teva Pharmaceuticals USA, Inc.$130
  • Alkermes, Inc.$112
  • AbbVie$108
  • plus $276 from 5 others

What the payments were for

  • Food & beverage$1,14399%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,158 in reported general payments places this provider in the 75th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$36,393
Medicare patients
30
Services billed
414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl14$51,087
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine106$2,733
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine32$1,722
Clozapine12$1,626
Ziprasidone Hcl20$1,070
Mirtazapine40$889
Quetiapine Fumarate33$850
Clonidine Hcl24$842
Venlafaxine Hcl ErVenlafaxine Hcl23$755
Lamotrigine56$678
Alprazolam45$655
Escitalopram Oxalate50$629
Sertraline Hcl37$611
Gabapentin40$554
Trazodone Hcl38$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$108$51,08714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →